Indacaterol/mometasone

Drug Profile

Indacaterol/mometasone

Alternative Names: Mometasone furoate/indacaterol acetate; Mometasone/indacaterol; QMF-149

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis; Schering-Plough
  • Developer Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Glucocorticoids; Indans; Pregnadienediols; Quinolones; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 25 Apr 2017 Novartis Pharmaceuticals initiates a phase III trial in Asthma in Japan (NCT03100500)
  • 17 Apr 2017 Chemical structure information added
  • 06 Apr 2017 Novartis plans a phase III trial for Asthma in Japan (NCT03100500)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top